The Dow Jones Industrial Average is climbing Wednesday morning with shares of UnitedHealth and Amgen seeing positive momentum for the blue-chip average. Shares of UnitedHealth and Amgen are ...

During the October 1 episode of Mad Money, Jim Cramer discussed Amgen Inc. (NASDAQ:AMGN) while reviewing the Dow Jones ...

Sept 22 () - Amgen said on Tuesday its experimental drug to treat an ‌autoimmune disease that attacks the body's ‌moisture-producing glands met the main goal of reducing disease ​activity in a ...

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Amgen has climbed to a recent close of US$407.44 after a strong multi year run, which puts fresh focus on whether that price ...

Shares of Amgen were recently down more than 9%, putting the biotechnology company on pace for its largest decrease since October 2000. The decline came after Novartis [announced a failure]( ...

Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning. Amgen ...

Amgen stock closed at USD 385.65 on September 18, 2026, up 1.55% and near the top of its recent trading range. The company now guides 2026 EPS as high as USD 23.50 and funds a USD 10.08 annual ...

Amgen just handed income investors another dividend raise, but a mountain of acquisition debt, crumbling legacy drugs, and a billion-dollar obesity bet are all competing for the same pool of cash.

Amgen drops after Novartis’ pelacarsen Phase 3 miss, pressuring olpasiran’s thesis amid patent cliffs. Click here to read an analysis of AMGN stock now.

Amgen stock recently closed at USD 385.65 on Nasdaq on September 18, 2026, leaving it close to the average analyst target near USD 387.69. Recent quarters have seen strong earnings momentum, ...